After grabbing 11702.0 shares, the institutional investor is now in possession of 11702.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.09% having worth around $5395.0. Moreover, UBS Securities LLC increased its share by 9665.0 to have a control over 9665.0 shares.
NeuroSense Therapeutics Ltd (NRSN) concluded trading on 12/14/23 at a closing price of $0.87, with 4.29 million shares of worth about $3.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.72% during that period and on Thursday the price saw a gain of about 27.93%. Currently the company’s common shares owned by public are about 11.78M shares, out of which, 9.09M shares are available for trading.
However, the stock later moved at a day high price of 0.9300, or with a gain of 27.93%. Stock saw a price change of 9.28% in past 5 days and over the past one month there was a price change of 77.53%. Year-to-date (YTD), NRSN shares are showing a performance of -28.70% which decreased to -44.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.40 but also hit the highest price of $2.91 during that period. The average intraday trading volume for NeuroSense Therapeutics Ltd shares is 786.75K. The stock is currently trading 8.16% above its 20-day simple moving average (SMA20), while that difference is up 37.07% for SMA50 and it goes to -29.69% lower than SMA200.
Citadel Securities LLC acquired 11702.0 shares of NeuroSense Therapeutics Ltd having value of about $5395.0. NeuroSense Therapeutics Ltd (NASDAQ: NRSN) currently have 11.78M outstanding shares and institutions hold larger chunk of about 5.72% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $11.85M and its 3Y-monthly beta is at 1.40. It has posted earnings per share of -$0.92 in the same period. It has Quick Ratio of 1.82. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NRSN, volatility over the week remained 14.46% while standing at 18.71% over the month.
Analysts are in expectations that NeuroSense Therapeutics Ltd (NRSN) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.19 and it is -$0.8 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.2 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 23.36% while it is estimated to decrease by -0.61% in next year.
